New Jersey's Hart and Celgene and Johnson & Johnson Executives Named to Scientific American Worldview 100 Most Influential People in Biotechnology

Trenton, NJ (June 18, 2015) - BioNJ President and CEO Debbie Hart, along with five other New Jersey executives, including Bob Hugin, Chairman and CEO, Celgene; Sol Barer, Ph.D., Founder, Celgene, and Managing Partner, SJ Barer Consulting; Robert Hariri, M.D., Ph.D., Chairman and Founder, Celgene Cellular Therapeutics; Paul Stoffels, M.D., CSO, Johnson & Johnson; and Shirley Tilghman, Ph.D., Professor, Molecular Biology, Princeton University, were named to the Worldview 100 as six of the 100 most influential people in biotechnology.

Scientific American Worldview, the annual custom edition on global biotechnology innovation, debuted today at the BIO International Convention in Philadelphia. Its' cover section this year, the Worldview 100, honors the world's most powerful people in biotechnology, as determined through nominations and selections from an international panel of experts and peers. Honorees include researchers, business experts, entrepreneurs and key media figures, all making a significant impact on the industry worldwide.

In addition to Hart, the Worldview 100 includes 26 prominent women within the biotechnology industry, including Melinda Gates, Co-Chair and Trustee, Bill & Melinda Gates Foundation; Margaret Hamburg, M.D., Former Commissioner, U.S. Food & Drug Administration; and Janet Woodcock, M.D., Director, Center for Drug Evaluation & Research, U.S. Food & Drug Administration.

In addition to Jim Greenwood, President and CEO, the Biotechnology Industry Organization (BIO), Hart is the only trade association executive named to the list.

Hart noted that she was "humbled to be included within the Worldview 100 and honored to be named for her life's passion in serving an industry that she loves. When I see the remarkable list of honorees, I am reminded of the dedication and passion that we have at work on the important job of bringing therapies and cures to the Patients who need them and it inspires me that we are in such good hands."

About BioNJ
BioNJ, The Gateway to Health, is a powerful network of 400 Member Investors representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can't Wait, BioNJ is committed to the growth and prosperity of New Jersey's life sciences ecosystem to help accelerate the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society. As the industry's voice in New Jersey, we fulfill our Mission to help our Members help Patients by driving capital formation and fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit

Randi Bromberg
Vice President, Communications and Marketing
O) 609-890-3185
C) 609-610-7526
[email protected]